glp-1 side effects muscle loss Exploring the of Receptor Agonist: To Ensure Its Optimal Positioning Reducore: Another natural GLP-1 without
Description
doi: 10.1016/J.CELREP.2013.06.018

June 25, 2024

GLP-1 receptor agonists (GLP-1 RAs), already established in the management of type 2 diabetes mellitus and obesity, have emerged as promising candidates for the treatment of nonalcoholic steatohepatitis (NASH), owing to their broad metabolic and hepatoprotective effects

The lin-12 locus specifies cell fates in Caenorhabditis elegans
Thondam SK, Cuthbertson DJ, Wilding JPH (2020) The influence of glucose-dependent insulinotropic polypeptide (GIP) on human adipose tissue and fat metabolism: implications for obesity, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD)
Tirzepatide additionally targets the GIP receptor, which may result in somewhat greater weight loss for certain patients
